TC Biopharm (Holdings) Plc Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
41TC BioPharm (Holdings)'s Business Model
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
About TC BioPharm (Holdings)
Website: https://www.tcbiopharm.com
CEO (Chief Executive Officer): Mr. Bryan L. Kobel
IPO date: 2022-02-11
Contact
Country: GB
Address: Maxim 1
City: Motherwell
State: None
Phone: 44 14 1433 7557
Zip Code: ML1 4WR
Other
CIK: 0001872812
ISIN: US87807D4007
CUSIP: 87807D103
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
